Business

May 9, 2014 11:08 AM

Durham drug developer Chimerix posts 1Q loss

Durham antiviral drug developer Chimerix posts a 1Q loss as it moves forward with its lead drug, brincidofovir, which is being developed to counter fatal viruses and bioterror attacks.

Related content

Suggested for you

Comments

Videos

Today's Market

Nasdaq
Powered by Barchart

Editor's Choice Videos